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Editorial
Point of View: Top-down or Bottom-up? A Cardiologist's View Point
on the Proposed Hospital Authority Initiative in Safe Introduction of
New Interventional Service
CHU-PAK LAU1 AND KAM-SANG WOO2
From 1Division of Cardiology, Department of Medicine, Queen Mary Hospital, University of Hong Kong and 2Prince
of Wales Hospital, Chinese University of Hong Kong, Hong Kong

In this issue of the Journal, Chang et al1 describes
a p r opos al mechanism for introduc ing n ew
interventional procedure in the Hospital Authority (HA).
As practising cardiologists, we would like to express a
different view on the proposed mechanism.
It is important first to define the scope of the
current initiative. The initiative addresses the territorywide application of new interventional procedures in
HA hospitals. As such, these procedures should be
relatively well established, with either international or
local evidence. Indeed, a formal ethics committee
approval is unnecessary, because this introduction is
service-oriented and is not a clinical trial. Chang et al1
quoted the application of brachytherapy as an example,
a procedure that has already been shown to be
efficacious and safe in several international randomized
controlled trials.2-3 New innovations which may be novel
treatment, usually carried out as a clinical trial would
need to go through hospital (or university) ethics
committee as stated in the current proposal, and these
trials will not need to go through the proposed HA
initiatives.
The proposed HA initiative is a typical "topdown" mechanism by which an administrative unit in
the HA, in conjunction with a few interested chosen
experts in the field, takes up "the governance and
management approval procedure" for new interventional
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procedures. Such a structure has the advantage of
ensuring a uniform protocol and training requirements
for all centers, and a central monitoring of quality.
The disadvantage of this mechanism is the
"representativeness" of the chosen experts, and the
necessary delay introduced by the administrative
process. For instance, a 6-month delay was encountered
between the application for β-brachytherapy to treat
coronary restenosis and the first case performed. In
addition, because of the rapid evolution of technology,
it may be necessary to repeat the whole process should
a close alternative be introduced. Thus, the mechanism
should build in an alternative is more expedite process,
to allow similar procedures to be approved. In some
hospitals such as the Queen Mary Hospital and Prince
of Wales Hospital, a third mechanism is operative: a
hospital based "Technology and Therapeutic
Subcommittee" is available to "approve" new
interventional procedures at the hospital level.
Traditionally, new interventional cardiology
procedures are introduced in Hong Kong by local
experts in the field, usually in the form of a clinical
trial. For example, the first radiofrequency ablation in
the Asia-Pacific region for paroxysmal supraventricular
tachycardia was introduced in Hong Kong in 1990.4
With training in the technique from the initiating center
in Hong Kong and centers overseas, this procedure is
now generally available in most of the HA hospitals
with catheterization laboratory. This process of
"evolution" from "bottom-up" has the advantage of
being highly flexible with minimal administrative cost
and burden, and with professional freedom that all of
us are used to and would like to continue. Patients'
welfare is safeguarded by the requirement of the ethics
committee, and by the expertise of the initiating
cardiologists. The quality of the service in subsequent
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centers are guaranteed by appropriate training, often
with participation of the cardiologists from the more
experience centers in the initial cases. Quality assurance
and accountability are in the hands of the practising
cardiologists and centres concerned. In the present
funding limitation in the HA in which there are little
additional funds for new procedures/services, these
procedures are introduced with "productivity gain" by
the unit concerned and is highly cost-effective.
Which system should we adopt? We think that
the "old" and "new" are not mutually exclusive, but
complementary. Most of the innovative treatments will
be carried out as clinical trials, under the auspicion of
individual hospital/university ethics committee. When
these innovations have matured to wider clinical
application, or when an established new interventional
procedure is for introduction, there may be a choice
between the "top-down" and "bottom-up" approach. We
believe that the clinicians, acting in the best interests of

2

the patients should have a freedom of choice in their
initiatives. Should additional funding from the HA be
available for introduction of new procedures, a "topdown" initiative would be a logical option.
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